AbbVie (4AB) Stock Forecast & Price Target

27 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4AB Analyst Ratings

Strong Buy

19 Buy

4 Hold

0 Sell

Based on 23 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€247.32

▲(11.66% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €247.32 with a high forecast of €276.92 and a low forecast of €197.80. The average price target represents a 11.66% change from the last price of €221.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"171":"€171","224":"€224","277":"€277","197.5":"€197.5","250.5":"€250.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":276.9155298,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€276.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247.31926682666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€247.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":197.796807,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€197.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[171,197.5,224,250.5,277],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,224.5,228.53196383076923,232.56392766153846,236.5958914923077,240.62785532307691,244.65981915384614,248.69178298461537,252.72374681538463,256.75571064615383,260.7876744769231,264.8196383076923,268.85160213846154,272.88356596923074,{"y":276.9155298,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,224.5,226.2553282174359,228.0106564348718,229.7659846523077,231.52131286974358,233.27664108717948,235.0319693046154,236.7872975220513,238.5426257394872,240.2979539569231,242.05328217435897,243.80861039179487,245.56393860923077,{"y":247.31926682666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,224.5,222.44590823076922,220.39181646153847,218.3377246923077,216.28363292307694,214.22954115384616,212.17544938461538,210.12135761538462,208.06726584615384,206.01317407692306,203.9590823076923,201.90499053846153,199.85089876923078,{"y":197.796807,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":172.829,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.336,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.631,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.929,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.055,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.279,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.551,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.37,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.372,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.613,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.161,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.7,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€276.92

Average Price Target€247.32

Lowest Price Target€197.80

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chris Schott

J.P. Morgan

€246.15→€250.54

Buy

13.11%

Upside

Reiterated

09/25/26

AbbVie (ABBV) Gets a Buy from J.P. Morgan

David Amsellem

Piper Sandler

€266.37

Buy

20.26%

Upside

Reiterated

09/23/26

Analysts' Top Healthcare Picks: AbbVie (ABBV), CytomX Therapeutics (CTMX)

Louise Chen

Scotiabank

€246.15

Buy

11.13%

Upside

Reiterated

09/22/26

AbbVie (ABBV) Receives a Buy from Scotiabank

Trung Huynh

RBC Capital

€246.15

Buy

11.13%

Upside

Reiterated

09/21/26

RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV)

Rajesh Kumar

HSBC

€263.73→€276.92

Buy

25.02%

Upside

Reiterated

09/10/26

AbbVie price target raised to $315 from $300 at HSBCAbbVie price target raised to $315 from $300 at HSBC

Luisa Hector

Berenberg Bank

€241.75

Buy

9.14%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and AbbVie (NYSE: ABBV)

Jason Gerberry

Bank of America Securities

€247.91

Buy

11.92%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Royalty Pharma (NASDAQ: RPRX) and Summit Therapeutics (NASDAQ: SMMT)

Geoff Meacham

Citi

€228.57

Hold

3.19%

Upside

Reiterated

09/04/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ionis Pharmaceuticals (NASDAQ: IONS) and AbbVie (NYSE: ABBV)

Steve Scala

TD Cowen

€246.15

Buy

11.13%

Upside

Reiterated

09/04/26

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Evan Seigerman

BMO Capital

€263.73

Buy

19.07%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€259.33→€263.73

Buy

19.07%

Upside

Assigned

08/17/26

AbbVie (ABBV) Receives a Buy from Wells Fargo

Alexandria Hammond

Wolfe Research

€263.73

Buy

19.07%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), AbbVie (NYSE: ABBV) and Establishment Labs Holdings (NASDAQ: ESTA)

Emily Field

Barclays

€263.73

Buy

19.07%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)

Gavin Clark-Gartner

Evercore ISI

€216.26→€228.57

Buy

3.19%

Upside

Assigned

08/10/26

AbbVie price target raised to $260 from $246 at Evercore ISIAbbVie price target raised to $260 from $246 at Evercore ISI

Hans Engel

Erste Group

―

Buy

―

Upgraded

08/05/26

AbbVie upgraded to Buy from Hold at Erste GroupAbbVie upgraded to Buy from Hold at Erste Group

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chris Schott

J.P. Morgan

€246.15→€250.54

Buy

13.11%

Upside

Reiterated

09/25/26

AbbVie (ABBV) Gets a Buy from J.P. Morgan

David Amsellem

Piper Sandler

€266.37

Buy

20.26%

Upside

Reiterated

09/23/26

Analysts' Top Healthcare Picks: AbbVie (ABBV), CytomX Therapeutics (CTMX)

Louise Chen

Scotiabank

€246.15

Buy

11.13%

Upside

Reiterated

09/22/26

AbbVie (ABBV) Receives a Buy from Scotiabank

Trung Huynh

RBC Capital

€246.15

Buy

11.13%

Upside

Reiterated

09/21/26

RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV)

Rajesh Kumar

HSBC

€263.73→€276.92

Buy

25.02%

Upside

Reiterated

09/10/26

AbbVie price target raised to $315 from $300 at HSBCAbbVie price target raised to $315 from $300 at HSBC

Luisa Hector

Berenberg Bank

€241.75

Buy

9.14%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and AbbVie (NYSE: ABBV)

Jason Gerberry

Bank of America Securities

€247.91

Buy

11.92%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Royalty Pharma (NASDAQ: RPRX) and Summit Therapeutics (NASDAQ: SMMT)

Geoff Meacham

Citi

€228.57

Hold

3.19%

Upside

Reiterated

09/04/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ionis Pharmaceuticals (NASDAQ: IONS) and AbbVie (NYSE: ABBV)

Steve Scala

TD Cowen

€246.15

Buy

11.13%

Upside

Reiterated

09/04/26

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Evan Seigerman

BMO Capital

€263.73

Buy

19.07%

Upside

Reiterated

09/03/26

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), AbbVie (ABBV)

Mohit Bansal

Wells Fargo

€259.33→€263.73

Buy

19.07%

Upside

Assigned

08/17/26

AbbVie (ABBV) Receives a Buy from Wells Fargo

Alexandria Hammond

Wolfe Research

€263.73

Buy

19.07%

Upside

Upgraded

08/13/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), AbbVie (NYSE: ABBV) and Establishment Labs Holdings (NASDAQ: ESTA)

Emily Field

Barclays

€263.73

Buy

19.07%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)

Gavin Clark-Gartner

Evercore ISI

€216.26→€228.57

Buy

3.19%

Upside

Assigned

08/10/26

AbbVie price target raised to $260 from $246 at Evercore ISIAbbVie price target raised to $260 from $246 at Evercore ISI

Hans Engel

Erste Group

―

Buy

―

Upgraded

08/05/26

AbbVie upgraded to Buy from Hold at Erste GroupAbbVie upgraded to Buy from Hold at Erste Group

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LFMDLifeMD

ORKAOruka Therapeutics

ACHVAchieve Life Sciences

PLSEPulse Biosciences

PMNProMIS Neurosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months

Carter GouldCantor Fitzgerald

Success Rate

13/17 ratings generated profit

Average Return

+9.40%

Copying Carter Gould's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +9.40% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

25/25 ratings generated profit

Average Return

+22.23%

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.23% per trade.

2 Years

Carter GouldCantor Fitzgerald

Success Rate

17/17 ratings generated profit

Average Return

+40.88%

Copying Carter Gould's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +40.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4AB has received 45 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 247.32.

Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €3.40 with a range of €3.38 to €3.47. The previous quarter’s EPS was €3.21. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €15.22B with a range of €15.12B to €15.36B. The previous quarter’s sales results were €14.94B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4AB has Performed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 247.32.

What is DE:4AB’s upside potential, based on the analysts’ average price target?

AbbVie has 11.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AbbVie a Buy, Sell or Hold?

AbbVie has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.

What is AbbVie’s share price target?

The average share price target for AbbVie is 247.32. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €276.92 ,and the lowest forecast is €197.80. The average share price target represents 11.66% Increase from the current price of €221.5.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of AbbVie?

To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AbbVie (4AB) Stock Forecast & Price Target

4AB Analyst Ratings

4AB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

4AB Analyst Recommendation Trends

4AB Financial Forecast

4AB Earnings Forecast

4AB Sales Forecast

4AB Stock Forecast FAQ

Detailed List of Analyst Forecasts